NEW YORK (GenomeWeb) – BG Medicine today said that its fourth quarter revenues were nearly halved year over year as both product and service revenues declined. 

The company separately announced that it filed a 510(k) premarket notification for clearance of an additional indication for the BGM Galectin-3 test. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.